Anti-vascular Endothelial Growth Factor Therapeutics (VEGF) Market - By Product, By Application - Global Forecast, 2025 - 2034

Anti-vascular Endothelial Growth Factor Therapeutics Market Size

The global anti-VEGF therapeutics market was valued at USD 13 billion in 2024 and is projected to exhibit 6.1% CAGR from 2025-2034. The rising awareness and demand for treatment are some of the factors that are driving revenues in the market. Aging population and increasing incidence of eye diseases are also contributing to the revenue growth.
 

The rising prevalence of eye diseases, such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion, is a significant driver of the anti-VEGF therapeutics market. These conditions are linked to abnormal blood vessel growth, which VEGF inhibitors effectively target, offering improved vision outcomes and disease management. According to the International Agency for the Prevention of Blindness (IAPB), over 196 million people globally are affected by AMD.
 

Additionally, the International Diabetes Federation (IDF) reports that diabetic retinopathy impacts nearly one-third of diabetic patients worldwide, reflecting the growing demand for VEGF inhibitors. With the aging population and rising diabetes incidence, the market for these therapies is expected to expand significantly, supported by increased accessibility to advanced treatments.
 

Anti-VEGF therapeutics are a class of targeted biological treatments designed to inhibit the activity of VEGF; a protein responsible for promoting the growth of new blood vessels (angiogenesis). These therapeutics are widely used in the management of diseases characterized by abnormal or excessive blood vessel formation, such as age-related macular degeneration (AMD), diabetic retinopathy, and certain cancers. By blocking VEGF, these therapies help to control disease progression and mitigate symptoms associated with pathological angiogenesis.
 

Anti-vascular Endothelial Growth Factor Therapeutics Market Trends

• The expansion of the market is fuelled by a number of important technological developments. The development of longer-acting formulations, including Eylea and Beovu, has greatly minimized the number of injections needed for patients with retinal conditions. Beovu, for instance, provides a 12-week dosing interval following the loading phase, enhancing convenience for patients and healthcare professionals alike.
   
• Moreover, Vabysmo is a more recent anti-VEGF therapy that acts on both VEGF and angiopoietin-2 (Ang-2), with the goal of treating multiple pathways in retinal disease. The dual mechanism of action offers improved treatment outcomes and possibly fewer injections than other treatments that act on only VEGF.
   
• Additionally, Lucentis (ranibizumab) has developed into newer drugs with enhanced pharmacokinetic profiles, lengthening the therapeutic effects. The production of biosimilars of Lucentis has also promoted cost-effectiveness in the market without compromising patients' access to effective therapy.
   
• In addition, the emergence of sustained-release implants for anti-VEGF treatment, For example, development for faricimab, represents a breakthrough in drug delivery technology that may enhance current anti-VEGF therapies like Eylea and Lucentis. This innovation could result in lower injection frequency and better patient outcomes.
   
• Finally, the developments in imaging and diagnostic sciences, including optical coherence tomography (OCT) and AI-enabled platforms, enable the monitoring of the conditions of the retina more accurately, allowing healthcare professionals to customize anti-VEGF treatment regimens, maximizing the dosing schedules of drugs like Beovu, Lucentis, and Vabysmo. These advances are major contributions to the growth and success of treatments available in the market.
   

Trump Administration Tariffs

• The anti-VEGF therapy market has been considerably impacted owing to the 2025 U.S. tariffs, particularly concerning the importation of drug and medical device.
   
• The U.S. has imposed a baseline 10% tariff on nearly all imports, which include medical devices and drugs. This has increased the burden on companies importing active pharmaceutical ingredients (APIs) and finished anti-VEGF therapy products.
   
• The imposed tariffs have disrupted the established global supply chains. The tariff burden is leading the companies such as Roche and Sanofi to shift production to the U.S., but these relocation processes are complex and expensive.
   
• Tariff impact can further cause many other pharmaceutical companies to shift their production overseas which can ultimately lead to the increased cost of anti-VEGF therapies resulting from the raised production expenses needed to keep profit margins sustainable. This is likely to impact the price and accessibility for patients who need treatment.
   

Anti-VEGF Therapeutics Market Analysis

Based on product, the market is segmented into Eylea, Lucentis, Beovu, Vabysmo, and other products. The Eylea segment dominates the market with a share of 51.8% in 2024.
 

• The most prominent segment in the market is Eylea, owing to its established efficacy and robust clinical performance for AMD and diabetic macular edema (DME) treatment. With a longer dosing regimen, Eylea provides fewer injections than other anti-VEGF treatments, making it more comfortable for patients and healthcare professionals, thus fueling its extensive adoption.
   
• In addition, Eylea has shown good safety and efficacy profiles in a number of clinical trials, and this has further established it as a treatment of choice for retinal diseases and has helped in its market leadership.
   
• However, Vabysmo, since its launch in 2022, is gaining rapid traction owing to its dual inhibition that improves vascular stability, and extended dosing interval, which can range up to 16 weeks.  
   

Based on application, the anti-VEGF therapeutics market is segmented into age-related macular degeneration, macular edema, retinal vein occlusion, diabetic retinopathy, myopic choroidal neovascularization, and other applications. The age-related macular degeneration segment dominated the market with a share of 46.5% in 2024.
 

• One of the primary drivers contributing to leading share of age-related macular degeneration (AMD) segment is an increasing prevalence of AMD, which is a progressive disorder that affects the macula of the retina and results in the loss of central vision, primarily in elderly age group.
   
• As stated in a National Center for Biotechnology Information study conducted in December 2024, AMD caused vision loss and blindness in 3.6 million people in 1990 and 8.1 million by 2021. The elderly population is experiencing a significant increase in vision loss, which is detrimentally impacting their quality of life and, in turn, creating a surge in demand for advanced therapeutic solutions in the AMD segment. 
   
• Moreover, substantial increase in the geriatric population is also anticipated to drive the demand for anti-VEGF therapeutics over the forecast period. As per the 2024 fact sheet of World Health Organization (WHO), nearly 1 in 6 individuals worldwide will be aged 60 years and older by 2030.
   

In 2024, the U.S. led the North America anti-VEGF therapeutics market, generating a revenue of about USD 6.7 billion.
 

• In the U.S., the population is aging rapidly, making them as one of the largest demographics affected with eye disorders such as AMD related vision loss. The American Academy of Ophthalmology claims that over 2.1 million citizens currently suffer with AMD, and this is bound to increase significantly in the following decades. There is a significant demand for retinal disease Eylea, Lucentis, and Beovu as anti-demand of anti-VEGF therapy is on the rise in the U.S., owing to its effectiveness in treating such disorders.
   
• Moreover, the U.S. has well-developed healthcare infrastructure and access to modern treatment options which aids the development of the market. The strong healthcare reimbursement program facilitates broadened access for patients to such therapies. This aids in the rapid adoption of such advanced treatments, expanding the market further.
   
• Furthermore, Medicare and private insurance plans classify ophthalmic Eylea, Lucentis, and Vabysmo as anti-VEGF injections eligible for reimbursement. With regards to biologic therapies, the available health insurance enables physicians in the U.S. to prescribe expensive branded options, which favors the revenue growth in the country.
   

Europe: UK is set to see a robust expansion in its anti-VEGF therapeutics market from 2025 to 2034.
 

• In the UK, the increasing prevalence of diabetic retinopathy and AMD is fuelling demand for anti-VEGF therapies, which is why their adoption is expected to grow. The use of anti- VEGF drugs like Lucentis and Eylea, that are preferably indicated for treating diabetic retinopathy and AMD is likely to increase as these diseases become more common.
   
• Moreover, NHS, which is among the largest publicly funded systems in the world, is equally instrumental in advancing the use of anti-VEGF therapies in UK. The NHS provides reimbursement for the implementation of modern treatment options. As a result, cutting-edge anti-VEGF drugs have become standard of care in the management of retinal disorders which increases market need.
   
• In addition, the UK is known for its developed healthcare policies which along with the introduction of new therapies enable the rapid incorporation of emerging drugs, which favors the adoption of anti-VEGF therapies in the country.
   

Asis Pacific: Japan's anti-VEGF therapeutics market is set for lucrative growth from 2024 to 2034.
 

• People aged 65 and above accounted for more than 30% of Japan's population in 2023 (The World Bank Group). This has economically strained the health system due to age-associated diseases like AMD. AMD, which requires high-cost and frequently-needed injections, is the major driver of demand for Anti-VEGF treatments.
   
• In addition, Japan has well established healthcare system, where a large part of the elderly population can access advanced medicines like Anti-VEGF injections. Japan’s National Health Insurance (NHI) reimburse the Anti-VEGF medications, ensuring lower cost burden on patients to increase their access to advanced therapies.
   
• Elderly peoples’ financial burden is lessened due to the fact that Anti-VEGF therapies such as Eylea (aflibercept) and Lucentis (ranibizumab) are covered by public health insurance in Japan. This contributes to the revenue growth in the country.
   

Middle East and Africa: Saudi Arabia's anti-VEGF therapeutics market is expected to witness substantial growth during the forecast period.
 

• Diabetic retinopathy and AMD awareness is increasing amongst the population of Saudi Arabia as the country has made significant advancements in healthcare awareness. The Saudis are now more inclined towards availing anti-VEGF therapy due to several awareness campaigns such as KSrelief Eye Care Missions which focus on early intervention and proper patient education.
   
• In addition, the Saudi Arabian government is working on improving the overall healthcare system as part of their Vision 2030 strategy, which aims to enhance the availability of advanced treatments and services to patients. There is also increased provision of anti-VEGF medications such as Beovu, Eylea, and Lucentis in the public and private medical sectors. Investment in healthcare infrastructure and provision of modern treatment options has a positive impact on the anti-VEGF market growth in the country.
   

Anti-vascular Endothelial Growth Factor Therapeutics Market Share

The market for the anti-vascular endothelial growth factor therapeutics encompasses a mix of local and international companies catering to the increasing opthalmic and onco therapies demand in ophthalmology and oncology. Established players such as Regeneron Pharmaceuticals, F. Hoffmann-La Roche, Bayer, and Novartis contributes to about 80% of the market.
 

In this market, the competition is driven by innovation, compliance with competitive regulations, and the ability to customize treatments suitable for providers such as hospitals, ophthalmology clinics, and cancer centers. In developing economies where cost is a primary concern, established international companies face the dilemma of how to provide competitively priced high quality anti-VEGF therapeutics. With the global players bound to maintain product advertisement, regional competitors take more beneficial route by providing inexpensive alternatives, forcing global competitors to reconsider their pricing without jeopardizing efficacy and compliance to regulations.
 

Anti-vascular Endothelial Growth Factor Therapeutics Market Companies

Some of the eminent market participants operating in the Anti-vascular Endothelial Growth Factor Therapeutics industry include:

• Alcon
• Amgen
• Bausch Health Companies
• Bayer
• Biogen
• Bristol-Myers Squibb
• Coherus BioSciences
• Eli Lilly and Company
• F. Hoffmann-La Roche
• Hoya Corporation
• Novartis
• Pfizer
• Regeneron Pharmaceuticals
• Sanofi
• Viatris
   

Anti-vascular Endothelial Growth Factor Therapeutics Industry News:

• In August 2023, Regeneron Pharmaceuticals, Inc. announced that the U.S. FDA approved EYLEA HD (aflibercept 8 mg) for the treatment of wet AMD and diabetic macular edema. Market authorization was granted based on the critical PULSAR and PHOTON trials which showed EYLEA HD achieved clinically similar vision improvements relative to EYLEA (aflibercept 2 mg) with less frequent injections. This has bolstered the company’s market position and enhanced competitiveness.
   
• In August 2024, the U.S. FDA approved Amgen’s Pavblu, marking it as the fifth Eylea biosimilar approved in the U.S. during 2024. The product is intended for wet AMD, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.
   
• In February 2025, Bayer announced that it has received approval from Health Canada for Eylea HD (aflibercept injection, 8mg) in a pre-filled syringe with integrated OcuClick dosing system for the treatment of wet AMD and diabetic macular oedema.
   
• In October 2021, Roche announced that the U.S. FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of neovascular or wet AMD in patients who had previously responded to at least two anti-VEGF injections.
   

The anti-VEGF therapeutics market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Eylea
• Lucentis
• Beovu
• Vabysmo
• Other products

Market, By Application

• Macular edema
• Diabetic retinopathy
• Retinal vein occlusion
• Age-related macular degeneration
• Myopic choroidal neovascularization
• Other applications

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE